Therapy for lysosomal storage disorders
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In the last years, much progress has been achieved in the field of lysosomal storage disorders. In the past, no specific treatment was available for the affected patients; management mainly consisted of supportive care and treatment of complications. As orphan drug regulations, however, encouraged development of drugs for these disorders by granting marketing exclusivity for 10 years and other commercial benefits, enzyme replacement therapy became available for lysosomal storage disorders, such as Gaucher disease, Fabry disease, mucopolysaccharidoses type I, II, and VI, and Pompe disease. This review will summarize the efficacy and clinical status of hematopoietic stem cell transplantation, enzyme replacement, and substrate deprivation therapy, and describe new therapeutic perspectives currently under preclinical investigations such as chaperone‐mediated therapy, stop‐codon read‐through therapy, and gene therapy. © 2009 IUBMB IUBMB Life, 62(1):33–40, 2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lysosomal disorders: From storage to cellular damage
Ballabio, A., & Gieselmann, V. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.12.001 · Cited by 571 · cited 3×
“2009 IUBMB IUBMB Life, 62(1): 33–40, 2010”
BackgroundInfluentialWorgall, S., Sondhi, D., Hackett, N. R., Kosofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.022 · Cited by 402 · cited 2×
“This procedure has been studied an animal model of late infantile neuronal ceroid lipofuscinosis (LINCL), a neurodegenerative lysosomal storage disorder, caused by mutations of the CLN2 (ceroid lipofuscinosis, neuronal 2) gene.”
MethodGene therapy for lysosomal storage diseases
Sands, M. S., & Davidson, B. L. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.006 · Cited by 285
Benjamin, E. R., Flanagan, J. J., Schilling, A., Chang, H. H., Agarwal, L., Katz, E., Wu, X., Pine, C., Wustman, B., Desnick, R. J., et al. (2009) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-009-1077-0 · Cited by 173 · cited 1×
“The concept of using inhibitors as chaperones has been investigated in cultured cells from patients with several lysosomal storage disorders such as Pompe disease (45), Gaucher disease (46), and Fabry disease (47).”
Background
Cited by
Mechtler, T. P., Stary, S., Metz, T. F., De Jesús, V. R., Greber-Platzer, S., Pollak, A., Herkner, K. R., Streubel, B., & Kasper, D. C. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61266-x · Cited by 297
The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives
Cherqui, S., & Courtoy, P. J. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.182 · Cited by 201
“Indeed, cross-correction , that is, the transfer of a functional protein from wild-type cells to deficient cells, has been well demonstrated in several lysosomal storage disorders caused by defective soluble hydrolases, after bone marrow transplantation or by recombinant enzyme infusion 178 .”
Tang, R., Kim, C. S., Solfiell, D. J., Rana, S., Mout, R., Velázquez-Delgado, E. M., Chompoosor, A., Jeong, Y., Yan, B., Zhu, Z.-J., et al. (2013) · ACS Nano · doi:10.1021/nn402753y · Cited by 188
Therapeutic applications of iminosugars: Current perspectives and future opportunities
Horne, G., & Wilson, F. X. (2011) · Progress in medicinal chemistry · doi:10.1016/b978-0-12-381290-2.00004-5 · Cited by 87
Newborn screening for lysosomal storage disorders and other neuronopathic conditions
Matern, D., Oglesbee, D., & Tortorelli, S. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1117 · Cited by 41
“Other therapeutic approaches, such as chemical chaperone therapy, substrate reduction therapy, gene therapy, and stop-codon read-through were used in clinical trials or were under development [Beck, 2010; Schiffmann, 2010; Urbanelli et al., 2011].”
Method
Metadata
- Authors
- Beck, M.
- Venue
- IUBMB Life
- Publisher
- Wiley
- Published
- 2009-12-14
- Volume
- 62
- Issue
- 1
- Pages
- 33-40
- ISSN
- 1521-6543 (ISSN-L)
- 1521-6551
- OpenAlex
- W2055335510
- Cited by
- 139
- References
- 4
- FWCI
- 12.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapy for lysosomal storage disorders. https://app.cochat.ai/papers/10.1002/iub.284
- The paper
- Beck, M. (2010). Therapy for lysosomal storage disorders. IUBMB Life. https://doi.org/10.1002/iub.284
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.